Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin B

Caleb P. Skipper,a,b Mucunguzi Atukunda,a Anna Stadelman,a,b Nicole W. Engen,b Ananta S. Bangdiwala,b Katherine H. Hullsiek,b Mahsa Abassi,b Joshua Rhein,b Melanie R. Nicol,b Eva Laker,a Darlisha A. Williams,b Raphael Mannino,c Theresa Matkovits,c David B. Meyea,b,d David R. Boulwareb

a Infectious Diseases Institute, Makerere University, Kampala, Uganda
b University of Minnesota, Minneapolis, Minnesota, USA
c Matinas Biopharma, Bedminster, New Jersey, USA
d College of Health Sciences, Makerere University, Kampala, Uganda

Caleb P. Skipper and Mucunguzi Atukunda are co-first authors. Author order was based on the number of years with the research team.

ABSTRACT Amphotericin B deoxycholate (AMB) has substantial toxicities. A novel encochleated amphotericin B deoxycholate (cAMB) formulation has oral bioavailability, efficacy in an animal model, and minimal toxicity due to targeted drug delivery into macrophages, where intracellular fungi reside. We conducted a phase I, ascending-dose trial of cAMB administered at 1.0 g, 1.5 g, or 2.0 g per day in 4 to 6 divided doses among HIV-positive survivors of cryptococcosis (n = 9 per cohort). We assessed the tolerability of cAMB and the adverse events (AEs) associated with cAMB treatment over 3 days. A second trial (n = 9) assessed the tolerability of 1.5 g/day given for 7 days. In the single-ascending-dose study, all subjects received their full daily dose without vomiting (100% tolerability). The cohort receiving 1.0 g had 4 transient clinical AEs in 2 subjects within 48 h and 8 laboratory AEs (n = 6 grade 2, n = 2 grade 1). The cohort receiving 1.5 g had 7 clinical AEs in 1 subject attributed to acute gastroenteritis (n = 4 grade 2) and 5 laboratory AEs (n = 1 grade 2). The cohort receiving 2.0 g had 20 clinical AEs among 5 subjects within 48 h (n = 3 grade 2) and 11 laboratory AEs (n = 2 grade 2, n = 1 grade 1). From a qualitative survey, 26 of 27 subjects (96%) preferred their experience with oral cAMB over their prior experience with intravenous (i.v.) AMB. The second, multiple-dose cohort received 1.5 g/day for 1 week, with 98.4% (248/252) of the doses being taken. Overall, 5 clinical AEs (n = 5 grade 1) and 6 laboratory AEs (n = 6 grade 1) occurred without kidney toxicity. Oral cAMB was well tolerated when given in 4 to 6 divided daily doses without the toxicities commonly seen with i.v. AMB. (This study has been registered at ClinicalTrials.gov under registration no. NCT04031833.)

KEYWORDS Cryptococcus, amphotericin B, pharmacokinetics, HIV, cryptococcal meningitis, antifungal agents, human immunodeficiency virus

Intravenously (i.v.) administered amphotericin B deoxycholate (AMB) is traditionally considered the vanguard antifungal therapy for serious fungal infections due to its broad activity and low resistance rates. However, i.v. AMB has numerous significant toxicities, including anemia, nephrotoxicity, and infusion-related reactions. Further, i.v. AMB has historically been available only as an intravenous medication, as oral absorption in humans is limited and causes toxicity (1). Encocchleated amphotericin B deoxycholate (cAMB; Matinas Biopharma Holdings, Bedminster, NJ) is a novel lipid nanocrystal formulation designed for targeted oral delivery of the classically intravenously administered antifungal.

The cAMB cochleates are comprised of a solid lipid bilayer sheet rolled into a spiral...
in which amphotericin molecules are trapped, along with calcium (Fig. 1). The drug is made biologically available when the cochleate is taken up by a phagocytic cell and a gradient between the high calcium concentration in the cochleate and the lower cytoplasmic calcium concentration is created. This results in the cochleate opening and releasing the amphotericin molecules. The cochleate structure provides protection against degradation in unfavorable environments (i.e., low pH in the stomach) while allowing targeted intracellular delivery into macrophages and reticuloendothelial cells.
The high intracellular concentrations allow for killing of intracellular organisms (such as fungi), while the low plasma concentrations reduce systemic toxicities.

cAMB demonstrates in vitro activity against *Cryptococcus neoformans*, *Candida* spp., and *Aspergillus fumigatus* (Matinas investigator brochure). In a cryptococcosis mouse model experiment by Williamson and colleagues, mice given cAMB at 25 mg/kg of body weight plus flucytosine (5FC) had rates of survival equivalent to those of mice injected with AMB plus 5FC (2). Further, these animal experiments demonstrated that cAMB is colocalized with cryptococcal yeast inside macrophages in the brain. Human data are also available for cAMB, including data from two unpublished noncryptococcosis clinical trials. One trial assessing the safety and efficacy of cAMB in vulvovaginal candidiasis (Clinical Trials.gov registration no. NCT02971007) demonstrated excellent safety at 400 mg/day with no serious adverse events (SAEs), although microbiological cure was suboptimal compared to that achieved with fluconazole. The second trial (Clinical Trials.gov registration no. NCT02629419) is ongoing in a small number of persons with azole-resistant severe chronic mucocutaneous candidiasis related to a primary immune deficiency. All these participants had a positive clinical response with symptom improvement scores and were able to take cAMB doses ranging from 200 to 800 mg for an extended duration, at least 18 months. In general, cAMB was well tolerated over a dose range of 200 mg to 800 mg among clinical study participants, with no evidence of hepatotoxicity, nephrotoxicity, or hypokalemia being detected. As single doses increase above 400 mg, gastrointestinal side effects (e.g., nausea, abdominal pain, bloating, diarrhea) occurred more frequently, likely due to unabsorbed cAMB.

Given the animal model efficacy and human safety data demonstrated in previous studies, cAMB is a promising therapeutic option for the treatment of invasive fungal infections, yet the optimal or maximum tolerated dose is unknown. We therefore designed an open-label phase I safety, tolerability, and dose-finding study of cAMB in HIV-positive Ugandans with a history of cryptococcal meningitis. Here, we present the results of participant tolerability and adverse events (AE) recorded in different dosing cohorts. Based on our phase I data, we plan to move cAMB to a phase II efficacy trial for HIV-associated cryptococcal meningitis.

**RESULTS**

In the initial single-ascending-dose trial, a total of 35 HIV-positive survivors of cryptococcal meningitis were screened. We enrolled 9 participants into each of the three sequential dosing cohorts: 1.0 g, 1.5 g, and 2.0 g per day. All participants were survivors of prior cryptococcal meningitis (median time since prior diagnosis, 46 months) and had previously received i.v. AMB for ~14 days. The median age was 36 years (interquartile range [IQR], 30 to 44 years), with 41% (11/27) of the participants being women. All participants were currently receiving antiretroviral therapy (ART), with 15 (42%) taking atazanavir and 37% (10/27) actively taking fluconazole at 200 mg as prophylaxis. The baseline characteristics are summarized in Table 1.

To meet the tolerability criteria, the participants were required to take the full daily dose without vomiting within 30 min after taking any dose, to report AEs of grade 2 or less, and to not discontinue the cAMB due to an AE or participant choice. For the cohorts receiving 1.0 g and 1.5 g, all 18 participants met the full tolerability criteria. In the cohort receiving 2.0 g, all 9 participants completed the dosing, but 1 participant experienced a grade 3 laboratory AE of transient thrombocytopenia at 48 h of unclear etiology. Therefore, only 89% (8/9) of the participants met the full tolerability criteria with dosing at 2.0 g.

Of the 27 participants in the phase IA study, 8 (30%) experienced at least one clinical AE. A total of 31 unique clinical AEs were reported, with 24 (77%) being grade 1 and 7 (23%) being grade 2. Increasing numbers of AEs correlated with increasing cAMB dose, with 65% (20/31) being recorded in the cohort receiving 2.0 g. No grade 3, grade 4, or serious AEs occurred. The most common clinical AEs were abdominal pain (n = 5), nausea (n = 5), and dizziness (n = 4). Of the same 27 participants, 15 (56%) experienced...
at least one laboratory AE. A total of 24 laboratory AEs were reported, with 14 (58%) being grade 1 and 9 (38%) being grade 2. There was one grade 3 adverse event, in which a participant in the cohort receiving 2.0 g had platelet counts of 163,000 and 160,000 cells/µl at baseline and 24 h, respectively, which then dropped to 31,000 cells/µl at 48 h. No platelet clumping was reported. The platelet count was repeated several times to ensure AE resolution; the count rebounded to 172,000 cells/µl by 2 weeks. The participant had no clinical deterioration or evidence of bleeding at the time of the documented thrombocytopenia. No grade 4 or serious laboratory AEs occurred. The most common laboratory AEs were an elevation in the total bilirubin level (n = 6), a mild isolated elevation in the aspartate transaminase (AST) level (n = 5), and mild sodium abnormalities (n = 2 hyponatremic; n = 3 hypernatremic) which met the National Institute of Allergy and Infectious Diseases (NIAID) Division of AIDS (DAIDS) criteria for a grade 1 AE (146 to 149 meq/liter) but which was within the normal range of the local College of American Pathologists (CAP)-certified laboratory for the population (138 to 150 meq/liter). Of the subjects with elevations in AST levels, only one was accompanied by an elevation in the alanine transaminase level, which occurred in a subject with chronic hepatitis B. The AE prevalence is summarized in Table 2.

A dose of 1.5 g was selected as the 100% tolerated phase IA study dose for use in phase IB of the study. The demographics of the 9 phase IB participants were similar to those of the phase IA participants. Eight of the 9 participants completed full dosing through 7 days, with 1 participant unintentionally missing 1 day of dosing. Three participants experienced a total of five grade 1 clinical AEs, with none being serious. Three participants also experienced a total of six grade 1 laboratory AEs, and again, none met the criteria for a serious AE. Overall, the participants from phase IB took cAMB successfully as outpatients and displayed minimal evidence of intolerance or toxicity with 7 days of continuous therapy.
The plasma concentrations of cAMB were measured at 0, 6, 12, 24, and 48 h from the time of cAMB initiation, and the area under the curve (AUC) was calculated. Interestingly, the plasma AUC from 0 to 48 h (AUC0–48) did not significantly differ across the three dosing cohorts, with the overall median being 2,200 ng · h/ml (P = 0.58) (Fig. 2).

Based on elimination between the 24-h and 48-h time points, the median half-life of cAMB was 48 h, and the median maximum concentration in plasma (Cmax) averaged across the three cohorts was 59.2 ng/ml (IQR, 48.8 to 74.0 ng/ml). In pharmacokinetic analyses of the phase IB cohort, the plasma concentration at 24 h (74.8 ng/ml) was 77% of the day 7 concentration of 97.7 ng/ml. At 72 h, the plasma concentration of 91.1 ng/ml was 93% of the day 7 concentration.

Using a qualitative scale, we assessed the impressions of the participants in the phase IA cohort of their experience with cAMB compared with their prior experience.

### Table 2 Adverse event summary

| Characteristic          | Phase IA | Phase IB (1.5 g) |
|-------------------------|----------|------------------|
| No. of participants     | Cohort 1 (1.0 g) | Cohort 2 (1.5 g) | Cohort 3 (2.0 g) | Phase IB (1.5 g) |
| No. of participants with SAEs | 0 | 0 | 0 | 0 |
| No. of participants with unexpected events | 0 | 0 | 0 | 0 |
| No. (%) of clinical events | 4 (100) | 3 (43) | 17 (85) | 5 (100) |
| Grade 1 | 0 | 4 (57) | 3 (15) | 0 |
| Grade 2 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |
| No. (%) of laboratory events | 8 (25) | 4 (80) | 8 (73) | 6 (100) |
| Grade 1 | 2 (25) | 4 (80) | 8 (73) | 6 (100) |
| Grade 2 | 6 (75) | 1 (20) | 2 (18) | 0 |
| Grade 3 | 0 | 0 | 1 (9) | 0 |
| Grade 4 | 0 | 0 | 0 | 0 |

The plasma concentrations of cAMB were measured at 0, 6, 12, 24, and 48 h from the time of cAMB initiation, and the area under the curve (AUC) was calculated. Interestingly, the plasma AUC from 0 to 48 h (AUC0–48) did not significantly differ across the three dosing cohorts, with the overall median being 2,200 ng · h/ml (P = 0.58) (Fig. 2). Based on elimination between the 24-h and 48-h time points, the median half-life of cAMB was 48 h, and the median maximum concentration in plasma (Cmax) averaged across the three cohorts was 59.2 ng/ml (IQR, 48.8 to 74.0 ng/ml). In pharmacokinetic analyses of the phase IB cohort, the plasma concentration at 24 h (74.8 ng/ml) was 77% of the day 7 concentration of 97.7 ng/ml. At 72 h, the plasma concentration of 91.1 ng/ml was 93% of the day 7 concentration.

Using a qualitative scale, we assessed the impressions of the participants in the phase IA cohort of their experience with cAMB compared with their prior experience.
with i.v. AMB. In the preparticipation survey, 40% (10/25) indicated that they would be willing to receive i.v. AMB again for their cryptococcal meningitis versus an alternative therapy. After completing the study follow-up, 96% (26/27) of the participants indicated they would prefer cAMB to i.v. AMB for cryptococcal meningitis treatment. Overall, 93% (25/27) thought that the multiple doses of cAMB were very convenient for therapy, whereas 65% (15/23) of the respondents thought that i.v. AMB was very convenient for therapy. One participant could not recall the initial i.v. AMB therapy. Nausea severity scoring was rated as “none” by 8 of 9 participants in the 1-g and 1.5-g cohorts and 7 of 9 participants in the 2.0-g cohort. In comparison, 25% (6/24) recalled severe nausea with i.v. AMB.

DISCUSSION

We found that cAMB administered in 4 to 6 divided daily doses was generally safe and tolerated in healthy HIV-positive Ugandans at doses of up to 2.0 g/day. While mild AEs were more frequently encountered as the dose was increased, 95% (34/36) of the participants completed all prescribed doses without a grade 3 or worse AE. It is worth noting that we found that 2017 DAIDS laboratory AE criteria occasionally graded a laboratory value (i.e., the sodium level) as a grade 1 event when the number fell within the reference range of the Ugandan population studied at our CAP-certified laboratory. Therefore, some of our grade 1 events may have been overreported. Based on our data, 1.5 g daily may represent the sweet spot of optimal tolerability versus dosing escalation.

cAMB appears to have a favorable toxicity profile compared to that of i.v. AMB. Data taken from the 177-participant COAT (cryptococcal optimal ART timing) trial (3) recorded 23 (13%) grade 3 to 5 AEs involving low serum potassium levels and 18 (10%) grade 3 to 5 AEs involving high serum creatinine levels, with all participants having received i.v. AMB. In comparison, our cAMB participants had no grade 3 or higher AEs involving potassium or creatinine, even when dosed for 7 days. Similar to the findings of previous unpublished studies (Matinas investigator brochure), our phase I data suggest that cAMB has much less electrolyte and kidney toxicity than i.v. AMB.

We found that smaller, frequent dosing helped mitigate the gastrointestinal side effects seen in early studies that utilized larger, one-time dosing. For example, a prior phase I study (CAM-102) of healthy volunteers given cAMB at 800 mg daily in a single dose reported that 58% (7/12) of participants developed a gastrointestinal AE (Matinas investigator brochure), whereas only 11% (2/18) of our participants developed any gastrointestinal AEs, despite receiving 1,000 and 1,500 mg daily with dosing divided 4 and 5 times daily, respectively. Further, our participants overwhelmingly declared that their subjective experience with cAMB was better than that with i.v. AMB.

We also demonstrated improved absorption and plasma concentrations of cAMB with smaller, frequent doses in phase I study volunteers. Given as a single 800-mg dose, the median AUC from 0 to 24 h (AUC\(_{0-24}\)) was 636 ng · h/ml and the mean \(C_{\text{max}}\) was 40.8 ng/ml (an ~7% increase compared to the \(C_{\text{max}}\) of 38.1 ng/ml achieved after a single 400-mg dose) (Matinas investigator brochure). In contrast, giving 1,000 mg in 4 to 6 divided doses increased the AUC\(_{0-24}\) to 990 ng · h/ml and the \(C_{\text{max}}\) to 64.9 ng/ml (~60% more than that after a single 800-mg dose). Interestingly, we saw negligible differences in \(C_{\text{max}}\) or AUC between our cohorts receiving divided doses of 1.0 g, 1.5 g, and 2.0 g (Fig. 2). This is hypothesized to be secondary to the targeted intracellular delivery of the drug and minimal drug in the plasma compartment, despite the improved absorption with divided dosing. Alternatively, there may have been a saturation of absorption, limiting increases in plasma concentrations; however, the current hypothesis based on data from animal studies is that plasma concentrations correlate poorly with antifungal activity, as increased oral cAMB dosing results in greater antifungal activity (4). We do note that cAMB plasma concentrations are an order of magnitude lower than the \(C_{\text{max}}\) reported with i.v. AMB in humans (1,430 ng/ml at a single 0.6-mg/kg dose) (5); thus, the pharmacokinetics of cAMB do not directly compare to those of i.v. AMB. The efficacy of cAMB in human fungal disease remains unknown,
and our phase II trial will provide important refinements in the pharmacokinetic/pharmacodynamic correlates for the treatment of cryptococcal meningitis with cAMB.

Our successful phase I cAMB trial does have limitations. We used survivors of prior cryptococcal meningitis for the advantage of the subjective comparison of cAMB to i.v. AMB; however, these participants may not have reported mild AEs as frequently, given their historical perspective of illness and daily concurrent antiretroviral and antibiotic use. In our pharmacokinetic analysis, the reported half-life represents an observed value, given our sampling time points, rather than the true elimination half-life.

Per our data safety monitoring board (DSMB) review, we are moving forward with a phase II randomized trial evaluating the efficacy of cAMB in HIV-positive Ugandans with cryptococcal meningitis using early fungicidal activity as the primary endpoint. Persons will be given stage-based incremental decreases in the i.v. AMB duration while concurrently increasing the AMB duration in order to determine cAMB efficacy while prioritizing participant safety. Based on our phase I data, we plan to use cAMB at 2.0 g daily with flucytosine for cryptococcal meningitis induction therapy, followed by cAMB at 1.5 g with fluconazole for 4 weeks of consolidation therapy. Persons with acute cryptococcal meningitis and elevated intracranial pressure commonly have significant nausea and vomiting, and therefore, the tolerability will be an ongoing area of monitoring. However, 2-week cryptococcal meningitis survivors discharged home with improving symptoms may find 1.5 g to be more tolerable for the additional 4 weeks of therapy. We began the phase 2 EnACT (encocleated oral amphotericin for cryptococcal meningitis) trial enrollment in July 2020. cAMB remains a promising novel antifungal in the fight against serious fungal infections, including cryptococcosis.

MATERIALS AND METHODS

We conducted a phase I safety and tolerability trial for cAMB in HIV-positive Ugandans from October 2019 to January 2020 in Kampala, Uganda (ClinicalTrials.gov registration no. NCT04031833). The trial was designed to occur in two sequential phases, with 27 participants enrolled in phase IA and 9 participants enrolled in phase IB. The participants in phase IA received a single ascending dose of cAMB sequentially administered at 1.0 g, 1.5 g, and 2.0 g per day in 4 to 6 divided doses, with 9 participants being used in each dose group. At least 6 of 9 participants had to tolerate the dose before proceeding to the next dosing cohort. Dose-limiting intolerability was defined as experiencing a grade 3 or higher AE, vomiting within 30 min after taking a dose, or discontinuing the medication due to an AE or toxicity. The participants in phase IB received the cAMB dose that was 100% tolerated in phase IA for 7 days to verify safety and tolerability with continuous dosing. Participants in phases IA and IB had the same inclusion and exclusion criteria.

Participants were recruited from a prior cryptococcal meningitis trial cohort (ASTRO-CM [adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis]; ClinicalTrials.gov registration no. NCT01802385) (6). All recruited subjects had a history of resolved HIV-associated cryptococcal meningitis and had received i.v. AMB previously. Inclusion requirements were an age of >18 years and a calculated creatinine clearance of >70 ml/min/1.73 m² (measured within 3 months). Participants were excluded if they exhibited a current illness, had a known untreated significant health problem, or had received amphotericin B therapy in the past 90 days. Women who were pregnant or breast-feeding were excluded.

Trial endpoints included (i) the proportion of the daily dose received and tolerated without vomiting within 30 min; (ii) the cumulative score of nausea, vomiting, and diarrhea by Common Terminology Criteria AE (CTCAE)-graded criteria (7); (iii) the incidence of adverse events (AEs) by the National Institute of Allergy and Infectious Diseases (NIAID) Division of AIDS (DAIDS) toxicity scale (version 2017) for grade 1 to 5 or serious AEs (SAEs) (8); and (iv) the participant subjective impression(s) of cAMB by visual analog and other scales. All clinical and laboratory AEs were followed up until resolution.

We collected plasma for pharmacokinetic analyses at 0, 6, 12, 24, and 48 h in phase IA. We monitored complete blood count, chemistries, and kidney and liver function tests at 0, 24, and 48 h, with follow-up occurring thereafter for any abnormal results. For phase IB, the same laboratory monitoring occurred at +1 day, +3 days, and +7 days for safety assessment and pharmacokinetic analyses. All laboratory measurements were performed at the IDI Core Laboratory, which is a College of American Pathologists (CAP)-certified laboratory and which participates in external quality assurance for all laboratory assays. Plasma drug quantification was conducted at Medpace Bioanalytical Laboratories (Medpace Inc., Cincinnati, OH) using an internally validated assay (MBL 17301). Briefly, 100 μl of plasma was placed in a 2-ml tube and fortified with internal standard working solution. The analyte and internal standard were extracted via protein precipitation using acetonitrile. The supernatant was then dried under a stream of nitrogen, and the resulting residue was reconstituted in 150 μl of 0.1% formic acid in methanol-water (1:1) before being submitted to liquid chromatography-tandem mass spectrometry analysis on a Sciex Qtrap or Triple Quad mass spectrometer.

Statistical analyses were primarily descriptive. The median and interquartile ranges or the number
ACKNOWLEDGMENTS

This research was made possible through support from the National Institute of Neurological Disorders and Stroke (grant RO1NS110519) and the Fogarty International Center (grant K01TW010268), including a combined grant via the Northern Pacific Global Health Fellows Program (grant D43TW009345), as well as the National Institute of Allergy and Infectious Diseases (grant T32AI055433).

We thank the research team: Bibiane Nakyejwe, Denis Ssenyondwa, Asmus Tukundane, John Kisembo, and Jesca Asienzo.

Two of the authors, Raphael Mannino and Theresa Matkovits, disclose that they are employees of the pharmaceutical sponsor. Specifically, the pharmaceutical sponsor manufactured and provided the study medication, provided the scientific know-how related to the drug delivery platform and the drug product, and led the regulatory interactions with FDA to support the conduct of the study under a U.S. IND. The sponsor also provided for the external measurement of amphotericin plasma concentrations. This is an investigator-initiated protocol, and the pharmaceutical sponsor did not influence the study conduct, analysis, or interpretation.

Conceptualization: Caleb Skipper, Nicole Engen, Katherine Huppler Hullsiek, Raphael Mannino, Theresa Matkovits, David B. Meyea, and David R. Boullware. Data curation: Anna Stadelman, Nicole Engen, Ananta Bangdiwala, and Katherine Huppler Hullsiek. Formal analysis: Nicole Engen, Katherine Huppler Hullsiek, Melanie R. Nicol, Caleb Skipper, and David R. Boullware. Investigation: Caleb Skipper, Mucunguzi Atukunda, Mahsa Abassi, David B. Meyea, and David R. Boullware. Methodology: Mucunguzi Atukunda, Caleb Skipper, David B. Meyea, and David R. Boullware. Project administration: Mucunguzi Atukunda and Darlisha A. Williams. Supervision: Mucunguzi Atukunda, Caleb Skipper, Joshua Rhein, Mahsa Abassi, Eva Laker, Nicole Engen, David B. Meyea, and David R. Boullware. Validation: Katherine Huppler Hullsiek, Caleb Skipper, David B. Meyea, and David R. Boullware. Visualization: Nicole Engen, Melanie R. Nicol, Caleb Skipper, David B. Meyea, and David R. Boullware. Writing and preparation of the original draft: Caleb Skipper and Mucunguzi Atukunda. Writing, review, and editing: Caleb Skipper, Mucunguzi Atukunda, Anna Stadelman, Nicole Engen, Ananta Bangdiwala, Katherine Huppler Hullsiek, Mahsa Abassi, Joshua Rhein, Eva Laker, Melanie R. Nicol, Darlisha A. Williams, Raphael Mannino, Theresa Matkovits, David B. Meyea, and David R. Boullware.

REFERENCES

1. Halde C, Newcomer VD, Wright ET, Sternberg TH. 1957. An evaluation of amphotericin B in vitro and in vivo against Coccidioides immitis and Candida albicans, and preliminary observations concerning the administration of amphotericin B to man. J Invest Dermatol 28:217–231. https://doi.org/10.1038/jid.1957.26.

2. Lu R, Hollingsworth C, Qiu J, Wang A, Hughes E, Xin X, Konrath KM, Elsegeiny W, Park YD, Atakulu L, Craft JC, Tramont EC, Mannino R, Williamson PR. 2019. Efficacy of oral encochleated amphotericin B in a murine model of cryptococcal meningoencephalitis. mBio 10:e00724-19. https://doi.org/10.1128/mBio.00724-19.

3. Boullware DR, Meyea DB, Muozora C, Rolfe MA, Huppler Hullsiek K, Musubire A, Taseera K, Nabetta HW, Schutz C, Williams DA, Rajasingham R, Rhein J, Thienemann F, Lo MW, Nielsen K, Bergemann TL, Kambugu A, Manabe YC, Janoff EN, Bohjanen PR, Meintjes G, COAT Trial Team. 2014. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med 370:2487–2498. https://doi.org/10.1056/NEJMoa1312884.

4. Delmas G, Park S, Chen ZW, Tan F, Kashiwazaki R, Zarif L, Perlin DS. 2002. Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob Agents Chemother 46: 2704–2707. https://doi.org/10.1128/aac.46.8.2704-2707.2002.

5. Bekkers I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. 2002. Pharmacokinetics, excretion, and mass balance of liposomal ampho-
tericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 46:828–833. https://doi.org/10.1128/AAC.46.3.828-833.2002.

6. Rhein J, Huppler Hullsiek K, Tugume L, Nuwagira E, Mpoza E, Evans EE, Kiggundu R, Pastick KA, Ssebambulide K, Akampurira A, Williams DA, Bangdiwala S, Abassi M, Musubire AK, Nicol MR, Muzoora C, Meya DB, Boulware DR, ASTRO-CM Team. 2019. Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial. Lancet Infect Dis 19:843–851. https://doi.org/10.1016/S1473-3099(19)30127-6.

7. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. 2017. Common terminology criteria for adverse events (CTCAE) v5.0. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bethesda, MD.

8. U.S. Department of Health and Human Services National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. 2017. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, corrected version 2.1. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bethesda, MD.